Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-3 long-term open-label extension of KarXT in psychosis associated with Alzheimer's disease
2023-504151-27-00Phase 3Authorised
- Sponsor
- Karuna Therapeutics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in Alzheimer's disease psychosis (ADP), sponsored by Karuna Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start May 2024; status: authorised.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on 2023-504151-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504151-27-00.